NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and...
Hence then, the article about rona therapeutics presents phase 1 data for rn0361 a long acting apoc3 targeting sirna at the american heart association 2025 scientific sessions was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions )
Also on site :
- 12-year old Russian beats world chess champion
- Body recovered from Lake Natoma amid search for missing man
- ‘The Princess Bride’ Star Cary Elwes Shares Tribute to Rob Reiner: ‘From That Very First Meeting I Fell In Love With Him’